Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

already on anticoagulation, or those with a new indication, who have not had PCI (medical management, CABG), continue anticoagulation and, unless there is a high risk of bleeding, consider continuing aspirin (or clopidogrel for people with contraindication for aspirin) for up to 12 months. [2020] 1.4.25 Do not routinely offer prasugrel or ticagrelor in combination with an anticoagulant that is needed for an ongoing separate indication for anticoagulation. [2020] 1.4.26 For people with an ongoing indication for anticoagulation 12 months after an MI, take into consideration all of the following when thinking about the need for continuing antiplatelet therapy: • indication for anticoagulation • bleeding risk • thromboembolic risk • cardiovascular risk • person's wishes. [2013] For a short explanation of why the committee made the 2020 recommendations and how they might affect practice, see the rationale and impact section on antiplatelet therapy for people with an indication for anticoagulation. Full details of the evidence and the committee's discussion are in evidence review G: combination therapy. Acute coronary syndromes (NG185) Beta-blockers 1.4.27 Offer people a beta-blocker as soon as possible after an MI, when the person is haemodynamically stable. [2013] 1.4.28 Communicate plans for titrating beta-blockers up to the maximum
